NASDAQ:KALA KALA BIO Q1 2026 Earnings Report $1.73 -0.36 (-17.22%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$1.75 +0.02 (+0.92%) As of 06/30/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast KALA BIO EPS ResultsActual EPS-$0.14Consensus EPS -$8.50Beat/MissBeat by +$8.36One Year Ago EPSN/AKALA BIO Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKALA BIO Announcement DetailsQuarterQ1 2026Date5/15/2026TimeBefore Market OpensConference Call DateFriday, May 15, 2026Conference Call Time7:00AM ETUpcoming EarningsKALA BIO's Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) KALA BIO Earnings HeadlinesKALA stock hits record low – firm announces reverse split after shares fail to surpass the $1 markMay 8, 2026 | msn.comKALA BIO Announces Reverse Stock SplitMay 7, 2026 | globenewswire.comSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page. | Weiss Ratings (Ad)How smart traders spot penny stock breakouts fastMay 1, 2026 | msn.comKala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic MedicineApril 21, 2026 | globenewswire.comKala Bio Delays 2025 Annual Report FilingApril 6, 2026 | theglobeandmail.comSee More KALA BIO Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like KALA BIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KALA BIO and other key companies, straight to your email. Email Address About KALA BIOKALA BIO (NASDAQ:KALA) (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis. Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions. These include formulations under development for dry eye disease and post-operative ocular inflammation, each leveraging the company’s nanoparticle platform to achieve higher local drug concentrations while potentially reducing systemic exposure. Preclinical and clinical programs are also exploring additional indications in retinal and anterior segment disorders. Founded in 2014 and headquartered in Watertown, Massachusetts, KALA Bio conducts research and development activities primarily in the United States. The company collaborates with academic institutions, specialty pharmacies and contract research organizations to support its clinical programs and regulatory filings. To broaden its global footprint, KALA Bio is evaluating strategic partnerships for potential expansion into European and Asian markets.View KALA BIO ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Wall Street Still Sees Massive Upside for AeroVironment StockManchester United’s Stock Rally Faces a Test Beyond Old TraffordBest Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs ProofPalantir’s Rough 2026 Start Raises a Bigger Question About Its AI MoatWinnebago Misses Estimates, But Surges 14% After EarningsBlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneTrip.com’s Selloff Raises a Bigger Question About Its Travel Recovery Story Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
